Advancement of Nanocarriers-based Therapeutics for Effective Management of Colorectal Cancer

Abstract

Background: Colorectal cancer is still challenging for scientists and healthcare professionals. Conventional treatment methods are associated with various limitations at a clinical bed and patient’s compliance. Novel nanocarrier based approaches opened a new window for improved therapy and new future perspective. Introduction: Cancer is the deadliest disease globally and is challenging to healthcare systems. Colorectal cancer (CRC) is the third most common cancer in the world, affecting all age groups and the most common cancer in 23 countries, as per the World Health Organization (WHO). Methods: In this review, we addressed nanocarriers based strategic treatment of colorectal cancer, major findings, limitations, and future perspective. For this, we seriously reviewed literature downloaded from prime sources such as Google Scholar, Web of Science, PubMed, and Publon. To filter the exact need of data, we used keyword alone in combination. Various relevant articles were obtained from the reference section of the selected papers. Results and Discussion: It is necessary to have an effective and targeted treatment option to control CRC compared to available remedies. Nanotechnology has been widely used to diagnose and treat several cancer types. Advances in nanomedicine and phytonanomedicine promoted novel identification methods to treat colorectal cancer patients. There are several nanocarriers recommended for clinical purposes. However, to date, only a few clinically approved nanocarriers can load anticancer moieties and selectively bind to cancer cells. Some nanocarriers transport and release treatments to the target colorectal area but provide few benefits. Conclusion: In this review, various nanoparticles (NPs) with unique properties have been discussed in relation to managing colorectal cancer, major outcomes of clinical trials, and successful patents published so far.